P-glycoprotein mediated efflux limits the transport of the novel anti-Parkinson's disease candidate drug FLZ across the physiological and PD pathological in Vitro BBB models

PLoS ONE

Volumn 9, Issue 7, 2014, Pages

  Liu, Qian ^a,b   Hou, Jinfeng ^a   Chen, Xiaoguang ^a   Liu, Gengtao ^a   Zhang, Dan ^a   Sun, Hua ^a   Zhang, Jinlan ^a  

^a INSTITUTE OF MATERIA MEDICA   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ANTIPARKINSON AGENT; BREAST CANCER RESISTANCE PROTEIN; FLUORESCEIN SODIUM; FUMITREMORGIN C; MULTIDRUG RESISTANCE PROTEIN; N 2 (4 HYDROXY PHENYL) ETHYL 2 (2,5 DIMETHOXY PHENYL) 3 (3 METHOXY 4 HYDROXY PHENYL)ACRYLAMIDE; UNCLASSIFIED DRUG; ZOSUQUIDAR; ABC TRANSPORTER; ABCG2 PROTEIN, RAT; BENZENEACETAMIDE DERIVATIVE; DIBENZO[A,D]CYCLOHEPTENE DERIVATIVE; INDOLE DERIVATIVE; PHENOL DERIVATIVE; QUINOLINE DERIVATIVE; SQUAMOSAMIDE; TRYPTOQUIVALINE;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; ATPASE ACTIVITY ASSAY; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG TRANSPORT; ELECTRIC RESISTANCE; IN VITRO STUDY; IN VIVO STUDY; MALE; MEMBRANE PERMEABILITY; NEUROPATHOLOGY; NEUROPHYSIOLOGY; NONHUMAN; PARKINSON DISEASE; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN TRANSPORT; RAT; TRANSEPITHELIAL ELECTRICAL RESISTANCE; ANIMAL; ANTAGONISTS AND INHIBITORS; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; MICROVASCULATURE; PATHOLOGY; PATHOPHYSIOLOGY; PERMEABILITY; TRANSPORT AT THE CELLULAR LEVEL; WISTAR RAT;

ADENOSINE TRIPHOSPHATASES; ANIMALS; ANTIPARKINSON AGENTS; ATP-BINDING CASSETTE TRANSPORTERS; BENZENEACETAMIDES; BIOLOGICAL TRANSPORT; BLOOD-BRAIN BARRIER; DIBENZOCYCLOHEPTENES; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; INDOLES; MALE; MICROVESSELS; P-GLYCOPROTEIN; PARKINSON DISEASE; PERMEABILITY; PHENOLS; QUINOLINES; RATS; RATS, WISTAR;

EID: 84904565430     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0102442     Document Type: Article

References (33)

1. Nagpal K, Singh SK, Mishra DN (2013) Drug targeting to brain: a systematic approach to study the factors, parameters and approaches for prediction of permeability of drugs across BBB. Expert Opin Drug Deliv.
2. Pardridge WM (2002) Drug and gene delivery to the brain: the vascular route. Neuron 36: 555-558.
3. Pardridge WM (2007) Blood-brain barrier delivery. Drug Discov Today 12: 54-61.
4. Abbott NJ, Patabendige AAK, Dolman DEM, Yusof SR, Begley DJ (2010) Structure and function of the blood-brain barrier. Neurobiology of Disease 37: 13-25.
5. ElAli A, Hermann DM (2011) ATP-Binding Cassette Transporters and Their Roles in Protecting the Brain. The Neuroscientist 17: 423-436.
6. Hou J, Qu F, Wu C, Ren Q, Zhang J (2012) Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 66: 232-239.
7. Rosenberg GA (2012) Neurological diseases in relation to the blood-brain barrier. Journal of Cerebral Blood Flow & Metabolism 32: 1139-1151.
8. Kong XC, Zhang D, Qian C, Liu GT, Bao XQ (2011) FLZ, a novel HSP27 and HSP70 inducer, protects SH-SY5Y cells from apoptosis caused by MPP(+). Brain Res 1383: 99-107.
9. Zhang D, Zhang JJ, Liu GT (2007) The novel squamosamide derivative FLZ protects against 6-hydroxydopamine-induced apoptosis through inhibition of related signal transduction in SH-SY5Y cells. Eur J Pharmacol 561: 1-6. (Pubitemid 46435837)
10. Feng W, Wei H, Liu GT (2005) Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism. Mol Neurobiol 31: 295-300. (Pubitemid 41271210)
11. Bao XQ, Kong XC, Qian C, Zhang D (2012) FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models. Neuroscience 202: 396-404.
12. Zlokovic BV (2008) The Blood-Brain Barrier in Health and Chronic Neurodegenerative Disorders. Neuron 57: 178-201.
13. Hastings TG, Lewis DA, Zigmond MJ (1996) Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc Natl Acad Sci U S A 93: 1956-1961. (Pubitemid 26079862)
14. Nakagawa S, Deli MA, Kawaguchi H, Shimizudani T, Shimono T, et al. (2009) A new blood-brain barrier model using primary rat brain endothelial cells, pericytes and astrocytes. Neurochem Int 54: 253-263.
15. Calabria AR, Weidenfeller C, Jones AR, de Vries HE, Shusta EV (2006) Puromycin-purified rat brain microvascular endothelial cell cultures exhibit improved barrier properties in response to glucocorticoid induction. J Neurochem 97: 922-933.
16. Nakagawa S, Deli MA, Nakao S, Honda M, Hayashi K, et al. (2007) Pericytes from brain microvessels strengthen the barrier integrity in primary cultures of rat brain endothelial cells. Cell Mol Neurobiol 27: 687-694. (Pubitemid 47476613)
17. Perriere N, Demeuse P, Garcia E, Regina A, Debray M, et al. (2005) Puromycin-based purification of rat brain capillary endothelial cell cultures. Effect on the expression of blood-brain barrier-specific properties. J Neurochem 93: 279-289. (Pubitemid 40547485)
18. Veszelka S, Pasztoi M, Farkas AE, Krizbai I, Ngo TK, et al. (2007) Pentosan polysulfate protects brain endothelial cells against bacterial lipopolysaccharide-induced damages. Neurochem Int 50: 219-228. (Pubitemid 44879678)
19. Gordon EL, Danielsson PE, Nguyen TS, Winn HR (1991) A comparison of primary cultures of rat cerebral microvascular endothelial cells to rat aortic endothelial cells. In Vitro Cell Dev Biol 27A: 312-326.
20. Weiss J, Rose J, Storch CH, Ketabi-Kiyanvash N, Sauer A, et al. (2007) Modulation of human BCRP (ABCG2) activity by anti-HIV drugs. J Antimicrob Chemother 59: 238-245. (Pubitemid 47072063)
21. Carvey PM, Zhao CH, Hendey B, Lum H, Trachtenberg J, et al. (2005) 6-Hydroxydopamine-induced alterations in blood-brain barrier permeability. European Journal of Neuroscience 22: 1158-1168. (Pubitemid 41395380)
22. Panula P, Joo F, Rechardt L (1978) Evidence for the presence of viable endothelial cells in cultures derived from dissociated rat brain. Experientia 34: 95-97. (Pubitemid 8261395)
23. Ogunshola OO (2011) In vitro modeling of the blood-brain barrier: simplicity versus complexity. Curr Pharm Des 17: 2755-2761.
24. Colgan OC, Collins NT, Ferguson G, Murphy RP, Birney YA, et al. (2008) Influence of basolateral condition on the regulation of brain microvascular endothelial tight junction properties and barrier function. Brain Res 1193: 84-92.
25. Prabhakarpandian B, Shen MC, Nichols JB, Mills IR, Sidoryk-Wegrzynowicz M, et al. (2013) SyM-BBB: a microfluidic blood brain barrier model. Lab Chip 13: 1093-1101.
26. Xue Q, Liu Y, Qi H, Ma Q, Xu L, et al. (2013) A novel brain neurovascular unit model with neurons, astrocytes and microvascular endothelial cells of rat. Int J Biol Sci 9: 174-189.
27. Deracinois B, Pottiez G, Chafey P, Teerlink T, Camoin L, et al. (2013) Glial-cell-mediated re-induction of the blood-brain barrier phenotype in brain capillary endothelial cells: a differential gel electrophoresis study. Proteomics.
28. Cecchelli R, Berezowski V, Lundquist S, Culot M, Renftel M, et al. (2007) Modelling of the blood-brain barrier in drug discovery and development. Nature Reviews Drug Discovery 6: 650-661. (Pubitemid 47202487)
29. Deli MA, Abraham CS, Kataoka Y, Niwa M (2005) Permeability studies on in vitro blood-brain barrier models: physiology, pathology, and pharmacology. Cell Mol Neurobiol 25: 59-127. (Pubitemid 40558585)
30. Grabb PA, Gilbert MR (1995) Neoplastic and pharmacological influence on the permeability of an in vitro blood-brain barrier. J Neurosurg 82: 1053-1058.
31. Cardoso FL, Brites D, Brito MA (2010) Looking at the blood-brain barrier: Molecular anatomy and possible investigation approaches. Brain Research Reviews 64: 328-363.
32. Tan KH, Dobbie MS, Felix RA, Barrand MA, Hurst RD (2001) A comparison of the induction of immortalized endothelial cell impermeability by astrocytes. Neuroreport 12: 1329-1334. (Pubitemid 32476123)
33. Poller B, Wagenaar E, Tang SC, Schinkel AH (2011) Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm 8: 571-582.